Prognostic Value of a Composite Score Including Baseline [ 18 F]FDG PET/CT and [ 68 Ga]Ga-PSMA PET/CT in Patients Screened for [ 177 Lu]Lu-PSMA Treatment Eligibility (the PROFILE Study) (EANM 2026) - Sep 29, 2026 - Abstract #EP-0929; "Aim/Introduction: We investigated the prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) and [68Ga]-prostate specific membrane antigen-11 ([68Ga] Ga-PSMA-11) PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu] Lu-PSMA-617 (LuPSMA)... The composite PROFILE score, implementing biological data and dual-tracer PET/CT imaging, offers valuable prognostic information in mCRPC patients who are candidates for LuPSMA therapy and may support patient selection."
Clinical • FDG PET • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Salivary Gland Cancer • Solid Tumor
|
|
A. Jougla 1; A. Giraudet 2; A. Olivier 3; P. Nunes 4; J. Blanc 4; A. Cochet 1; S. Ladoire 5; J. Vrigneaud 1; L. Vija 6; C. Drouet 1
|